LTHUQ yields 20000000.00% · JNJ yields 2.13%● Live data
📍 LTHUQ pulled ahead of the other in Year 1
Combined, LTHUQ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LTHUQ + JNJ for your $10,000?
Lithium Technology Corporation engages in the design, manufacture, marketing, and delivery of rechargeable energy storage solutions. The company designs and builds large format cylindrical lithium-ion (Li-ion) rechargeable cells, as well as Li-ion rechargeable batteries with battery management systems for use in transportation, military/national security, and stationary power markets. Its product portfolio includes large format high power cells ranging from 7.5 to 45 Ah with high discharge capabilities designed for HEV and military applications; high energy cells ranging from 10 to 485 Ah for various applications, such as back-up power and remote standby installations; large batteries up to 600V and capacity of more than 1.2 MWh; and standard cells that are assembled into custom large batteries complete with electronics to manage the batteries. The company markets its products to industrial, retail, and government customers, as well as to scientific research facilities and national defense agencies primarily in the United States, United Kingdom, and Germany. Lithium Technology Corporation is headquartered in Fairfax, Virginia. On December 5, 2014, Lithium Technology Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Virginia.On June 12, 2015, the voluntary petition of Lithium Technology Corp. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on December 5, 2014.
Full LTHUQ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.